ASH 2022 | Advances in cellular therapies for lymphoma: the value of CAR-T therapy & optimizing patient outcome
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses updates and current advancements in CAR-T cell therapy for various subtypes of lymphoma. Dr Westin anticipates that CAR-T cells will play a large role in the field of cancer therapy in the coming years, providing an effective treatment strategy for all patients, including elderly and frail patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy, Research Funding; MorphoSys/Incyte Corporation: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Calithera: Consultancy, Research Funding; Iksuda: Consultancy; ADC Therapeutics: Consultancy, Research Funding; MonteRosa: Consultancy; AstraZeneca: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Merck: Consultancy; Abbvie/GenMab: Consultancy; SeaGen: Consultancy.
